Back to results
US 12,472,187 B2Granted
Texaphyrin-Pt(IV) conjugates and compositions for use in overcoming platinum resistance
AssigneeBoard of Regents, The University of Texas System
InventorsJonathan L. Sessler, Jonathan Arambula, Zahid H. Siddik, Gregory Thiabaud
Life of this patent
Estimating the term…
Abstract
The present disclosure relates platinum(IV) and texaphyrin linked conjugates and compositions comprising a texaphyrin and a platinum(IV) agent. The present disclosure also provides pharmaceutical compositions of the conjugates and compositions. Also, provided herein are methods of using the instant compounds in the treatment of cancer such as a platinum resistant cancer.
Claims21
A compound of the formula:
- wherein:
- R1 and R2 are each independently selected from hydrogen, halo, hydroxy, amino, mercapto, alkoxy(C<12), substituted alkoxy(C<12), and
- wherein n is 1-20 and R3 is hydrogen, alkyl(C≤6), substituted alkyl(C≤6), or a platinum (IV) chelating group;
- A1 and A2 are each independently selected from hydrogen, halo, hydroxy, alkyl(C≤12), substituted alkyl(C≤12), alkoxy(C<12), substituted alkoxy(C<12), and
- wherein n is 1-20 and R3 is hydrogen, alkyl(C≤6), substituted alkyl(C≤6), or a platinum (IV) chelating group;
- Y1, Y2, Y3, and Y4 are each independently selected from hydrogen, halo, alkyl(C≤12), and substituted alkyl(C≤12);
- X1, X2, X3, X4, X5, and X6 are each independently selected from hydrogen, hydroxy, halo, amino, carboxy, nitro, cyano,
- alkyl(C≤12), alkenyl(C≤12), aryl(C≤12), and a substituted version of any of these groups, or
- a platinum chelating group of the formula:
- -A3-X7-A4-R4, wherein A3 and A4 are each independently alkanediyl(C≤12), alkoxydiyl(C≤12), alkylaminodiyl(C≤12), or a substituted version of any of these groups, X7 is —NR5—, —C(O)NR5—, or —NR5C(O)—, wherein R5 is hydrogen, alkyl(C≤12), or substituted alkyl(C<12), and R4 is
- wherein:
- R6 is amino, or carboxy;
- L3, L4, and L6 are each ligands independently selected from aqua, ammonia, halide, or hydroxide, or
- L3 and L6 are taken together and are alkyldicarboxylate(C≤18), aryldicarboxylate(C≤18), or a substituted version of any either group;
- L5 is aqua, amino, nitrate, sulfate, halide, nitrate, sulfate, or hydroxide,
- alkylamine(C≤12), cycloalkylamine(C≤12), dialkylamine(C≤18), dicycloalkylamine(C≤18), arylamine(C≤12), diarylamine(C≤18), heteroarene(C≤12), alkylcarboxylate(C≤12), arylcarboxylate(C≤12), and a substituted version of any of these groups;
- L7 is amino or L4 and L7 are taken together and arc diaminocycloalkane(C≤12), or substituted diaminocycloalkane(C≤12);
- provided that at least one of X1, X2, X3, X4, X5, and X6 is a platinum (IV) chelating group;
- M is a trivalent lanthanide metal ion;
- and
- L1 and L2 are each anionic ligands independently selected from fluoride, chloride, bromide, perchlorate, nitrate, sulfate, trifluoromethylsulfonate, acetate, and trifluoroacetate;
- or a pharmaceutically acceptable salt thereof.
19 more elements
Dependencies are inferred from the claim text.